With systemic lupus erythematosus, kidney disease reduces life expectancy an average of 15 years
Predictors of moderate-severe SLE flare at week 52 identified using three indicators
A 50% or greater reduction in proteinuria after six months of treatment for severe lupus nephritis predicted better 15-year renal survival.
In a recent study researchers examined transplant outcomes in patients with lupus nephritis who had no clinical evidence of disease in the year prior.
Lupus nephritis patients can be good candidates if their disease is quiescent for at least one year prior to surgery.
Genetic changes may partly explain why African-Americans with lupus are up to five times more likely develop end-stage kidney disease.
SLE patients with renal failure often continue to experience flares, but most commonly these are serologic rather than clinical.
If a lupus patient has never had renal disease, pregnancy, in and of itself, is not likely to increase that risk.
Even partial recovery in lupus nephritis patients lowers the risk of needing dialysis or a kidney transplant.
Effects of MMF may be influenced by the pathogenesis and/or cellular micro-environments unique to each disease process.
Approximately 30%-50% of SLE patients have clinically evident renal disease at presentation, but renal involvement occurs in up to 60% of patients overall.
The American College of Rheumatology (ACR) has issued new guidelines for screening, treating, and managing lupus nephritis (LN), including methods of identifying kidney disease, newer therapies, and pregnant patient care.
Adding rituximab to mycophenolate mofetil and corticosteroids does not improve outcomes in patients with lupus nephritis (LN), according to a study.
Black race is associated with worse renal transplant outcomes among patients with lupus nephritis and focal segmental glomerulosclerosis (FSGS), according to two studies presented at Kidney Week, the annual meeting of the American Society of Nephrology.
Mycophenolate mofetil (MMF) is more effective than azathioprine as maintenance therapy for patients with active lupus nephritis (LN) who responded to induction therapy, researchers reported.
CHICAGO—Adding abatacept to mycophenolate mofetil (MMF) and steroids does not significantly improve the time to complete renal response in patients with lupus nephritis (LN), according to the findings of a 12-month study presented at the 2011 American College of Rheumatology annual meeting.
CHICAGO—Vascular biomarkers may forecast impending flare or flare outcome in patients with lupus nephritis (LN), according to researchers in New York.
CHICAGO—Certain features at the time of renal biopsy are associated with a particular class of lupus nephritis (LN) and may independently predict good renal outcomes, according to a new Canadian study presented at the 2011 American College of Rheumatology Annual Scientific Meeting.
ATLANTA—Prolonged immunoadsorption (IAS) decreases proteinuria and leads to sustained stabilization of lupus nephritis in patients with highly active systemic lupus erythematosus (SLE), according to long-term results of a small Austrian study. The treatment did not result in tumors, anaphylaxis, or orthostatic events.
ATLANTA—Mortality rates from lupus nephritis have decreased significantly since 1975 but have leveled off over the past 10 years, British researchers found.
ATLANTA—Lupus nephritis patients who receive rituximab earlier in the course of their disease rather than later have better outcomes, new findings suggest.
ATLANTA—Enteric-coated mycophenolate sodium (EC-MPS) in combination with steroids is a viable therapy for lupus nephritis, according to an Italian study presented at the American College of Rheumatology annual meeting.
ATLANTA—A low-dose combination of mycophenolate mofetil (MMF) and tacrolimus (TAC) may be a viable option for treating refractory lupus nephritis, according to a new study by Chinese investigators.
Contrary to previous studies, lupus patients who receive kidney transplants rarely develop lupus nephritis in their new allograft, according to a study presented at ASN's Renal Week conference.
Rituximab is an effective treatment for lupus nephritis that enables reductions in maintenance steroids, data show.
Prior history of treatment with pulse methylprednisolone may increase the risk of fatal infection in pediatric lupus nephritis (LN) patients treated with IV cyclophosphamide (IVCY), researchers reported.
Pregnant patients with active lupus nephritis have a higher incidence of maternal and fetal complications compared with patients who have systemic lupus erythematosus (SLE) without renal involvement, researchers reported in Lupus (2009;18:342-347).
SAN FRANCISCO—Preventing renal damage in patients with systemic lupus erythematosus (SLE) may be critical to lowering their mortality rate, according to a new report.
SAN FRANCISCO—Lupus nephritis (LN) in adolescents responds similarly to mycophenolate mofetil (MMF) and IV cyclophosphamide, according to data reported at the American College of Rheumatology (ACR) annual meeting here.
SAN FRANCISCO—Patients with lupus nephritis (LN) who experience renal flares incur nearly double the direct medical costs over one year compared with those who not have flares, data suggest.